| Alex Stewart Stagnaro-green, MD | |
|
30 Bergen St, Admc 12 1205, Newark, NJ 07107-3000 | |
| (973) 972-0037 | |
| Not Available |
| Full Name | Alex Stewart Stagnaro-green |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine - Endocrinology, Diabetes & Metabolism |
| Location | 30 Bergen St, Newark, New Jersey |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1124052048 | NPI | - | NPPES |
| 8898502 | Medicaid | NJ |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RE0101X | Internal Medicine - Endocrinology, Diabetes & Metabolism | 25MA04622800 (New Jersey) | Primary |
| Entity Name | The Board Of Trustees Of The University Of Illinois |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1386863819 PECOS PAC ID: 3072422716 Enrollment ID: O20031112000158 |
News Archive
A mutant protein found in nearly all pancreatic cancers plays a role not only in the cancer's development but in its continued growth, according to a new study from University of Michigan Comprehensive Cancer Center researchers. The finding suggests a possible target for developing new ways to treat this deadly disease.
Idera Pharmaceuticals, Inc. today presented data showing that IMO-4200, a dual agonist of Toll-like receptor (TLR) 7 and TLR8, in combination with approved cancer treatments, rituximab or bortezomib, significantly increased antitumor activity in several preclinical lymphoma models. The presentation, entitled "Antitumor Activity of an RNA-Based Agonist of TLR7 and 8 in Preclinical Models of Hematological Malignancies," was made at the 52nd Annual Meeting of the American Society for Hematology in Orlando, Florida by Idera scientists.
Pharmaceuticals commonly found in the environment are disrupting streams, with unknown impacts on aquatic life and water quality.
Until late last week, help seemed close. In 2012, the city's Taxi and Limousine Commission had voted to take six cents on every fare for a fund that would help with exactly these kinds of situations, providing upwards of $300 per week in assistance as soon as a driver could produce a doctor's note.
Imagine cutting down the growth of cancer cells at their earliest stages to halt tumor growth. Research conducted by leading cancer metabolism researchers at Stony Brook University, Paul M. Bingham, PhD, and Zuzana Zachar, PhD, is showing promise in this approach with their clinical investigation of a new class of compounds that disrupt cancer cell mitochondrial metabolism.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Alex Stewart Stagnaro-green, MD 30 Bergen St, Admc 12 1205, Newark, NJ 07107-3000 Ph: () - | Alex Stewart Stagnaro-green, MD 30 Bergen St, Admc 12 1205, Newark, NJ 07107-3000 Ph: (973) 972-0037 |
News Archive
A mutant protein found in nearly all pancreatic cancers plays a role not only in the cancer's development but in its continued growth, according to a new study from University of Michigan Comprehensive Cancer Center researchers. The finding suggests a possible target for developing new ways to treat this deadly disease.
Idera Pharmaceuticals, Inc. today presented data showing that IMO-4200, a dual agonist of Toll-like receptor (TLR) 7 and TLR8, in combination with approved cancer treatments, rituximab or bortezomib, significantly increased antitumor activity in several preclinical lymphoma models. The presentation, entitled "Antitumor Activity of an RNA-Based Agonist of TLR7 and 8 in Preclinical Models of Hematological Malignancies," was made at the 52nd Annual Meeting of the American Society for Hematology in Orlando, Florida by Idera scientists.
Pharmaceuticals commonly found in the environment are disrupting streams, with unknown impacts on aquatic life and water quality.
Until late last week, help seemed close. In 2012, the city's Taxi and Limousine Commission had voted to take six cents on every fare for a fund that would help with exactly these kinds of situations, providing upwards of $300 per week in assistance as soon as a driver could produce a doctor's note.
Imagine cutting down the growth of cancer cells at their earliest stages to halt tumor growth. Research conducted by leading cancer metabolism researchers at Stony Brook University, Paul M. Bingham, PhD, and Zuzana Zachar, PhD, is showing promise in this approach with their clinical investigation of a new class of compounds that disrupt cancer cell mitochondrial metabolism.
› Verified 2 days ago
Dr. Xiaoning Joanie Zhu, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 741 Broadway, Newark, NJ 07104 Phone: 973-481-1300 | |
Lissette Maria Cespedes, M.D. Endocrinology, Diabetes & Metabolism Medicare: Medicare Enrolled Practice Location: 185 S Orange Ave, Msb I588, Newark, NJ 07103 Phone: 973-972-3479 | |
Dr. Pankaja Achar, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 194 Clinton Ave Fl 2, Newark, NJ 07108 Phone: 973-273-1515 Fax: 973-230-0883 | |
Marc H. Lavietes, M.D. Endocrinology, Diabetes & Metabolism Medicare: Medicare Enrolled Practice Location: 90 Bergen St, Doc 4500, Newark, NJ 07103 Phone: 973-972-2500 Fax: 973-972-2510 | |
Dr. Hoi-wing Susanna Yim, M.D. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 111 Central Ave, Newark, NJ 07102 Phone: 973-877-5000 | |
Tharakeswari Selvakumar, MD, PHD Endocrinology, Diabetes & Metabolism Medicare: Medicare Enrolled Practice Location: 150 Bergen St # Uhi-248, Newark, NJ 07103 Phone: 973-972-6056 | |
Dr. Epifania Lopez Ramirez, M.D. Endocrinology, Diabetes & Metabolism Medicare: Medicare Enrolled Practice Location: 1119 Broad St, Newark, NJ 07114 Phone: 973-824-8226 Fax: 973-824-0193 |